Abstract
COVID-19 emerged in Wuhan, China, but was caused by the original coronavirus, severe acute respiratory syndrome associated coronavirus-2 (SARS-CoV2). In early 2020, there was a widespread breakout of cases well over world, resulting in an epidemic that rapidly escalated to become a pandemic. This abruptly shook the global healthcare system. The emergence of the alpha, beta, and delta SARS-CoV-2 were associated with new waves of infections, sometimes across the entire world but until this month i.e., between Nov-Dec, 2021, Delta variant reigned supreme until the emergence of a newer variant i.e., Omicron (B.1.1.529) of SARS-CoV-2. Delta had 13 mutations. Of these, nine are in the spike protein, the protrusion on the surface of the virus that helps it latch onto human cells. Specifically, two are in a molecular hook, called the “receptor-binding domain”. Omicron, a creation caused by monstrous mutations. At least 32 mutations are in the spike protein and 10 in the receptor-binding domain. was designated a COVID-19 variant of concern (VoC) by the World Health Organization (WHO) on 26th November 2021. Structurally, the omicron variant has shown too mutated at antibody binding sites which would leverage them for escaping the possible immune response by the body. We don’t yet know much about the other alterations and how they might affect the virus’s behavior. Omicron COVID-19 strain after identifying individuals with symptoms that were not the same as those seen in the Delta form. People with night sweats have also been reported. The new omicron variant has more mutations than the prevailing rampant delta virus. This makes the newer variant more transmissible, better able to evade itself from various vaccines readily available in the current scenario. These overall increases in the percentage changes in a single day cases of COVID-19 reported cases can be attributed to the beginning of third wave or can be speculated as newer surge of omicron variant cases. Yet another new variant has been detected in France with 46 mutations and 37 deletions in its genetic code, many affecting the spike protein. ‘B.1.640.2’ is the current nomenclature for this variation.
Acknowledgment
We are thankful to Prof. Dr. Vikas Bhatia, Executive Director, All India Institute of Medical Sciences, Bibinagar, Telangana, 508126, India.
-
Research funding: None.
-
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Competing interest: None to declare.
-
Ethical approval: Not applicable.
References
1. World Health Organization. Classification of omicron (B.1.1.529): SARS-CoV-2 variant of concern; 2021. Available from: https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern.Search in Google Scholar
2. Poudel, S, Ishak, A, Perez-Fernandez, J, Garcia, E, León-Figueroa, DA, Romaní, L, et al.. Highly mutated SARS-CoV-2 Omicron variant sparks significant concern among global experts – what is known so far? Trav Med Infect Dis 2022;45:102234. https://doi.org/10.1016/j.tmaid.2021.102234.Search in Google Scholar PubMed PubMed Central
3. Vaughan, A. Omicron emerges. New Sci 2021;252:7. https://doi.org/10.1016/S0262-4079(21)02140-0.Search in Google Scholar PubMed PubMed Central
4. GISAID. hCov19 variants; 2021. Available from: https://www.gisaid.org [Accessed 2 Dec 2021].Search in Google Scholar
5. GISAID. hCov19 variants; 2021. Available from: https://www.gisaid.org [Accessed 4 Dec 2021].Search in Google Scholar
6. Beaumont, P. Omicron Covid variant’ present in Europe at least 10 days ago. Available from: https://www.theguardian.com/world/2021/nov/30/omicron-covid-variant-present-in-europe-at-least-10-days-ago [Accessed 2 Dec 2021].Search in Google Scholar
7. Gu, H, Krishnan, P, Ng, DYM, Chang, LDJ, Liu, GYZ, Cheng, SSM, et al.. Probable transmission of SARS-CoV-2 omicron variant in quarantine hotel, Hong Kong, China, November 2021. Emerg Infect Dis 2022;28:460–62. https://doi.org/10.3201/eid2802.212422.Search in Google Scholar PubMed PubMed Central
8. Balsamo, M, Miller, Z. The white house just announced the first confirmed U.S. Case of the omicron variant of COVID-19. Available from: https://time.com/6125101/first-us-omicron-case’ [Accessed 2 Dec 2021].Search in Google Scholar
9. Centers for Disease Prevention and Control. Science brief: omicron (B.1.1.529) variant; 2021. Available from: https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-omicron-variant.html [Accessed 4 Dec 2021].Search in Google Scholar
10. Karim, S, Karim, Q. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. Lancet 2021;398:2126–28. https://doi.org/10.1016/s0140-6736(21)02758-6.Search in Google Scholar
11. Corum, J, Zimmer, C. Tracking omicron and other coronavirus variants; 2021. Available from: https://www.nytimes.com/interactive/2021/health/coronavirus-variant-tracker.html [Accessed 2 Dec 2021].Search in Google Scholar
12. Kamble, P, Daulatabad, V, John, N, John, J. Synopsis of symptoms of COVID-19 during second wave of the pandemic in India. Horm Mol Biol Clin Investig 2021;43:97–104. https://doi.org/10.1515/hmbci-2021-0043.Search in Google Scholar PubMed
13. The new variant “Omicron” crowded out “delta” and swept South Africa. Available from: https://mbd.baidu.com/newspage/data/landingsuper?context=%7B%22nid%22%3A%22news_9303524037907362042%22%7D&n_type=−1&p_from=−1 [Accessed 29 Nov 2021].Search in Google Scholar
14. Ministry if heath and family welfare, state data; Available from: www.mohfw.gov.in [Accessed 7 Jan 2022].Search in Google Scholar
15. WHO. Weekly epidemiological update on COVID-19 – 28 September 2021. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports [Accessed 29 Nov 2021].Search in Google Scholar
16. Pfizer. Pfizer’s novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate [Accessed 20 Nov 2021].Search in Google Scholar
17. Owen, DR, Allerton, CMN, Anderson, AS, Aschenbrenner, L, Avery, M, Berritt, S, et al.. An oral SARSCoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science 2021;374:1586–93. https://doi.org/10.1126/science.abl4784.Search in Google Scholar PubMed
18. World Health Organization. WHO advice for international traffic in relation to the SARS-CoV-2 Omicron variant (B.1.1.529) [Internet]; 2021. Available from: https://www.who.int/news-room/articles-detail/who-advice-for-international-traffic-in-relation-to-the-sars-cov-2-omicron-variant.Search in Google Scholar
19. World Health Organization. Enhancing readiness for Omicron (B.1.1.529): technical brief and priority actions for member states: 17 December 2021 [Internet]; 2021. Available from: https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-states [Cited 23 Dec 2021].Search in Google Scholar
20. Colson, P, Delerce, J, Burel, E, Dahan, J, Jouffret, A, Fenolla, F, et al.. Emergence in southern France of a new SARS-CoV-2 variant of probably cameroonian origin harbouring both substitutions N501Y and E484K in the spike protein. Arch Virol 2022;167:1185–90. https://doi.org/10.1007/s00705-022-05385-y.Search in Google Scholar PubMed PubMed Central
© 2022 Walter de Gruyter GmbH, Berlin/Boston
